Comprehensive Study Notes: Myasthenia Gravis vs. Glaucoma

Overview of Autonomic Nervous System Dysfunctions

  • System Function: The autonomic nervous system regulates involuntary physiological processes throughout the body.

  • Mechanisms of Failure: Pathologies of the autonomic nervous system manifest through distinct underlying physiological mechanisms rather than a uniform pathway:

    • Receptor-Level Communication Failure: Characterized by profound neurotransmitter imbalances and autoimmune-mediated receptor destruction (exemplified by Myasthenia Gravis).

    • Structural Fluid Dynamics Failure: Driven by dysregulation of fluid pathways and pathologically elevated physical pressure (exemplified by Glaucoma).

Myasthenia Gravis: Pathophysiology and Cascade

  • Disease Definition: A chronic autoimmune neuromuscular junction disorder characterized by progressive, fatiguable skeletal muscle weakness.

  • Pathophysiologic Mechanism:

    • The immune system produces autoantibodies that target, block, and destroy nicotinic acetylcholine receptors at the postsynaptic neuromuscular junction.

    • Despite motor nerves firing and releasing acetylcholine, muscle fibers fail to receive adequate chemical signals due to the physical destruction of functional receptors.

  • Step-by-Step Pathophysiologic Cascade:

    1. Autoimmune Attack: Production of circulating autoantibodies targeting postsynaptic acetylcholine receptors.

    2. Receptor Depletion: Severe quantitative reduction and loss of available acetylcholine receptors.

    3. Impaired Transmission: When a nerve impulse arrives, an insufficient quantity of acetylcholine binds to receptors, leading to an incomplete muscle contraction.

    4. Clinical Manifestation: Progressive muscle fatigability wherein repeated muscle use directly increases weakness.

Primary Open-Angle Glaucoma: Pathophysiology and Fluid Dynamics

  • Disease Definition: A progressive optic neuropathy characterized by structural damage to the optic nerve head, leading to predictable visual field loss.

  • Pathophysiologic Mechanism:

    • Glaucoma is driven by increased physical resistance within the eye's aqueous humor drainage apparatus.

    • Inability to clear aqueous fluid leads to fluid buildup, elevated intraocular pressure, and mechanical compression/ischemia of the optic nerve.

  • Aqueous Humor Outflow Pathways:

    • Primary Pathway (Trabecular Meshwork): Clears 85 %85\,\% of total aqueous humor from the eye. Clogging or physical resistance within this pathway is the primary root cause of primary open-angle glaucoma.

    • Secondary Pathway (Uveoscleral Outflow Pathway): Clears the remaining 15 %15\,\% of aqueous humor outflow.

Triggers and Clinical Presentations

  • Myasthenia Gravis Presentation:

    • Physical Symptoms: Visible, fatiguable weakness including drooping eyelids (ptosis), double vision (diplopia), and difficulty swallowing (dysphagia).

    • Systemic Stress Triggers: Everyday stressors can trigger exacerbations, including active infections, surgical procedures, pregnancy, or extreme stress.

    • Exacerbating Pharmacologic Agents:

      • Beta-blockers.

      • Antibiotics (specifically fluoroquinolones and aminoglycosides).

      • Magnesium sulfate.

    • Medical Emergency (Myasthenic Crisis): Severe exacerbation causing profound weakness of the respiratory muscles, resulting in an inability to breathe without mechanical ventilation.

  • Primary Open-Angle Glaucoma (POAG) Presentation:

    • Physical Symptoms: Silent and insidious onset.

    • Visual Field Loss: Causes gradual, painless loss of peripheral vision without ocular redness, often remaining undetected by the patient until late stages.

  • Primary Angle-Closure Glaucoma (PACG) Presentation:

    • Physical Symptoms: Acute, sudden-onset attack featuring severe eye pain, perception of halos around light sources, and a fixed mid-dilated pupil.

    • Anatomic Triggers: Any event inducing pupillary dilation (mydriasis), causing the iris to bunch up and occlude the iridocorneal drainage angle.

    • Demographic and Structural Risk Factors: Advanced age, female sex, and farsightedness (hyperopia).

    • Exacerbating Pharmacologic Agents:

      • Anticholinergics.

      • Adrenergic agonists (e.g., pseudoephedrine found in over-the-counter cold remedies).

      • Tricyclic antidepressants.

    • Medical Emergency: Acute angle closure causes immediate intraocular pressure spikes that can lead to rapid, permanent vision loss without immediate intervention.

Diagnostic Workups and Modalities

  • Myasthenia Gravis Diagnostic Tools:

    • Edrophonium (Tensilon) Test: Intravenous administration of edrophonium (a short-acting acetylcholinesterase inhibitor) temporarily halts acetylcholine degradation, causing muscle weakness to temporarily reverse.

    • Serologic Testing: Assays detecting circulating anti-acetylcholine receptor (anti-ACHR) antibodies, which test positive in approximately 85 %85\,\% of cases.

    • Electrophysiological Testing: Repetitive nerve stimulation and single-fiber electromyography (SFEMG) evaluate electrical transmission, detecting decremental response or increased jitter as proof of signal degradation.

    • Chest Computed Tomography (CT): Performed to screen for a thymoma (tumor of the thymus gland), present in 10 %10\,\% to 15 %15\,\% of Myasthenia Gravis patients, which acts as a key driver of the autoimmune response.

  • Glaucoma Diagnostic Tools:

    • Tonometry: Measures intraocular pressure. Normal baseline intraocular pressure is below 21 mmHg21\,\text{mmHg}. In an acute glaucoma attack, values can shoot past 40 mmHg40\,\text{mmHg} or 50 mmHg50\,\text{mmHg}.

    • Fundoscopic Examination: Direct visualization of the back of the eye to inspect for optic nerve head cupping (physical structural damage caused by pressure).

    • Visual Field Testing: Maps out functional loss of peripheral vision.

    • Gonioscopy: Uses a specialized lens to evaluate whether the iridocorneal drainage angle is physically open or closed.

Pharmacotherapy Strategies

  • Myasthenia Gravis Pharmacotherapy:

    • First-Line Treatment: Pyridostigmine, an acetylcholinesterase inhibitor that blocks the enzymatic breakdown of acetylcholine, increasing its availability in the synaptic cleft to bind remaining functional receptors.

    • Immunomodulation: Corticosteroids or immunosuppressants used to reduce autoantibody production.

    • Emergent Intervention: Plasmapheresis used during a myasthenic crisis to physically filter and wash attacking autoantibodies out of the patient's blood.

  • Glaucoma Pharmacotherapy:

    • Therapeutic Objective: Lower intraocular pressure to prevent optic nerve damage.

    • First-Line Treatment for Open-Angle Glaucoma: Prostaglandin analogues (e.g., latanoprost), which increase fluid drainage through the secondary uveoscleral outflow pathway.

    • Aqueous Humor Production Inhibitors: Beta-blockers, which decrease fluid production within the eye.

    • Miotics: Agents like pilocarpine, which physically contract/stretch the trabecular meshwork to increase fluid outflow.

Clinical Cross-Over and Safety Paradox

  • Inter-System Pharmacological Hazard:

    • Beta-blockers are a standard, highly effective treatment used to lower intraocular pressure in glaucoma by suppressing fluid production.

    • However, beta-blockers impair neuromuscular transmission at the skeletal muscle junction.

  • Clinical Paradox:

    • Administering a beta-blocker to treat glaucoma in a patient who also has Myasthenia Gravis can impair neuromuscular transmission so severely that it triggers profound muscle weakness, drooping eyelids, difficulty breathing, or a life-threatening myasthenic respiratory crisis.

    • If a patient receiving beta-blockers for glaucoma suddenly presents with severe muscle weakness, ptosis, and dyspnea, clinicians must evaluate for unmasked or exacerbated Myasthenia Gravis.